Movement Alert｜MicroPort MedBot Rises 5.84% in Regular Trading, Toumai Commercialization Milestones Continue to Drive Momentum

Market Focus07-03

On July 3, MicroPort MedBot-B rose 5.84% in regular trading, trading at HK$25.62/share, with turnover of HK$87.19 million. The rally was driven by continued market enthusiasm over the Toumai laparoscopic surgical robot's multiple commercialization milestones, compounded by broad strength across Hong Kong-listed robotics concept stocks.

On the news front, the company recently announced that Toumai's global commercial installations surpassed 200 units, with the 200th deployed at Spain's HM Hospitales. All installations have received end-customer acceptance reports. Global commercial orders have exceeded 300 units, with total orders approaching 400. Notably, new orders in the first half already surpassed the full-year total of the prior year. In June, Toumai's remote surgery full-department application received EU CE certification, making it the world's first remote surgical robot to obtain this approval, with regulatory clearance in nearly 20 countries and regions.

CITIC Construction Investment maintains a Buy rating on the company, citing strong overseas volume growth and expecting total revenue to double year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120181692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120181692","market":"hk","top_or_hot":-1,"title":"Movement Alert｜MicroPort MedBot Rises 5.84% in Regular Trading, Toumai Commercialization Milestones Continue to Drive Momentum","media":"Market Focus","content":"<p><p>On July 3, MicroPort MedBot-B rose 5.84% in regular trading, trading at HK$25.62/share, with turnover of HK$87.19 million. The rally was driven by continued market enthusiasm over the Toumai laparoscopic surgical robot's multiple commercialization milestones, compounded by broad strength across Hong Kong-listed robotics concept stocks.</p><p>On the news front, the company recently announced that Toumai's global commercial installations surpassed 200 units, with the 200th deployed at Spain's HM Hospitales. All installations have received end-customer acceptance reports. Global commercial orders have exceeded 300 units, with total orders approaching 400. Notably, new orders in the first half already surpassed the full-year total of the prior year. In June, Toumai's remote surgery full-department application received EU CE certification, making it the world's first remote surgical robot to obtain this approval, with regulatory clearance in nearly 20 countries and regions.</p><p>CITIC Construction Investment maintains a Buy rating on the company, citing strong overseas volume growth and expecting total revenue to double year-over-year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜MicroPort MedBot Rises 5.84% in Regular Trading, Toumai Commercialization Milestones Continue to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜MicroPort MedBot Rises 5.84% in Regular Trading, Toumai Commercialization Milestones Continue to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, MicroPort MedBot-B rose 5.84% in regular trading, trading at HK$25.62/share, with turnover of HK$87.19 million. The rally was driven by continued market enthusiasm over the Toumai laparoscopic surgical robot's multiple commercialization milestones, compounded by broad strength across Hong Kong-listed robotics concept stocks.</p><p>On the news front, the company recently announced that Toumai's global commercial installations surpassed 200 units, with the 200th deployed at Spain's HM Hospitales. All installations have received end-customer acceptance reports. Global commercial orders have exceeded 300 units, with total orders approaching 400. Notably, new orders in the first half already surpassed the full-year total of the prior year. In June, Toumai's remote surgery full-department application received EU CE certification, making it the world's first remote surgical robot to obtain this approval, with regulatory clearance in nearly 20 countries and regions.</p><p>CITIC Construction Investment maintains a Buy rating on the company, citing strong overseas volume growth and expecting total revenue to double year-over-year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1120181692","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120181692","pubTimestamp":1783044188,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, MicroPort MedBot-B rose 5.84% in regular trading, trading at HK$25.62/share, with turnover of HK$87.19 million. The rally was driven by continued market enthusiasm over the Toumai...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"动感快讯|微创MedBot常规交易涨5.84%图迈商业化里程碑持续推动动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"On July 3, MicroPort MedBot-B rose 5.84% in regular trading, trading at HK$25.62/share, with turnover of HK$87.19 million. The rally was driven by continued market enthusiasm over the Toumai laparoscopic surgical robot's multiple commercialization milestones, compounded by broad strength across Hong Kong-listed robotics concept stocks.On the news front, the company recently announced that Toumai's global commercial installations surpassed 200 units, with the 200th deployed at Spain's HM Hospitales. All installations have received end-customer acceptance reports. Global commercial orders have exceeded 300 units, with total orders approaching 400. Notably, new orders in the first half already surpassed the full-year total of the prior year. In June, Toumai's remote surgery full-department application received EU CE certification, making it the world's first remote surgical robot to obtain this approval, with regulatory clearance in nearly 20 countries and regions.CITIC Construction Investment maintains a Buy rating on the company, citing strong overseas volume growth and expecting total revenue to double year-over-year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120181692","isCrawlerRequest":true}